Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost?

Area of Science:

• Oncology
• Medical Research

Background:

• Pancreatic cancer is a highly fatal disease with limited second-line treatment options.
• There is a lack of prospective studies on second-line therapies for pancreatic cancer.
• Establishing a standard second-line treatment approach is crucial due to treatment challenges like cost, efficacy, and toxicity.

Purpose of the Study:

• To investigate and compare the efficacy and toxicity of different second-line treatment regimens for metastatic pancreatic cancer.
• To provide data for informed decision-making in the second-line management of pancreatic cancer.

Main Methods:

• Retrospective analysis of patient files diagnosed with metastatic pancreatic cancer.
• Inclusion criteria: patients older than 18 who received first-line chemotherapy and progressed.
• Data collected from Ege University Hospital medical oncology department between 2013 and 2017.

Main Results:

• Median progression-free survival was 3.2 months for Xelox, 3.7 months for gemcitabine-nab paclitaxel, and 3.5 months for other regimens.
• Median overall survival was 5.9 months for Xelox, 5.3 months for gemcitabine-nab paclitaxel, and 4.8 months for other regimens.
• No statistically significant difference was observed between the treatment groups for primary or secondary endpoints.

Conclusions:

• Second-line treatment options for metastatic pancreatic cancer demonstrated comparable outcomes in terms of survival.
• Treatment selection should involve a comprehensive evaluation of drug costs and side effect profiles in addition to efficacy.
• Further prospective studies are warranted to establish optimal second-line treatment strategies.